<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1313</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>12421934</PubmedId>
            <Abstract>Although mice transgenic (Tg) for human MHC (HLA) class I alleles could provide an important model for characterizing HLA-restricted viral and tumor Ag CTL epitopes, the extent to which Tg mouse T cells become HLA restricted in the presence of endogenous H2 class I and recognize the same peptides as in HLA allele-matched humans is not clear. We previously described Tg mice carrying the HLA-B27, HLA-B7, or HLA-A2 alleles expressed as fully native (HLA(nat)) (with human beta(2)-microglobulin) and as hybrid human/mouse (HLA(hyb)) molecules on the H2(b) background. To eliminate the influence of H2(b) class I, each HLA Tg strain was bred with a H2-K(b)/H2-D(b)-double knockout (DKO) strain to generate mice in which the only classical class I expression was the human molecule. Expression of each HLA(hyb) molecule and HLA-B27(nat)/human beta(2)-microglobulin led to peripheral CD8(+) T cell levels comparable with that for mice expressing a single H2-K(b) or H2-D(b) gene. Influenza A infection of Tg HLA-B27(hyb)/DKO generated a strong CD8(+) T cell response directed at the same peptide (flu nucleoprotein NP383-391) recognized by CTLs from flu-infected B27(+) humans. As HLA-B7/flu epitopes were not known from human studies, we used flu-infected Tg HLA-B7(hyb)/DKO mice to examine the CTL response to candidate peptides identified based on the B7 binding motif. We have identified flu NP418-426 as a major HLA-B7-restricted flu CTL epitope. In summary, the HLA class I Tg/H2-K/H2-D DKO mouse model described in this study provides a sensitive and specific approach for identifying and characterizing HLA-restricted CTL epitopes for a variety of human disease-associated Ags.</Abstract>
            <ArticleYear>2002</ArticleYear>
            <ArticlePages>5571-80</ArticlePages>
            <ArticleTitle>Human MHC class I transgenic mice deficient for H2 class I expression facilitate identification and characterization of new HLA class I-restricted viral T cell epitopes.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Cheuk</LastName>
                    <ForeName>Eve</ForeName>
                </Author>
                <Author>
                    <LastName>D'Souza</LastName>
                    <ForeName>Celine</ForeName>
                </Author>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Ningjie</ForeName>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Youan</ForeName>
                </Author>
                <Author>
                    <LastName>Lang</LastName>
                    <ForeName>Haili</ForeName>
                </Author>
                <Author>
                    <LastName>Chamberlain</LastName>
                    <ForeName>John W</ForeName>
                </Author>
            </Authors>
            <Affiliations>Research Institute, Program in Infection, Immunity, Injury and Repair, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada, M5G 1X8.</Affiliations>
            <ArticleChemicalList>Epitopes, T-Lymphocyte;H-2 Antigens;H-2K(K) antigen;H-2Kb protein, mouse;HLA Antigens;HLA-B7 Antigen;Histocompatibility Antigens Class I;Immunodominant Epitopes;Immunoglobulin Variable Region;NP protein, Influenza A virus;Nucleoproteins;RNA-Binding Proteins;Viral Core Proteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; CD8-Positive T-Lymphocytes(immunology; metabolism; virology); Cytotoxicity Tests, Immunologic; Epitopes, T-Lymphocyte(analysis; immunology; metabolism); Gene Rearrangement, beta-Chain T-Cell Antigen Receptor; H-2 Antigens(biosynthesis; genetics); HLA Antigens(biosynthesis; genetics; immunology); HLA-B7 Antigen(immunology; metabolism); Histocompatibility Antigens Class I(biosynthesis; genetics; immunology); Humans; Immunodominant Epitopes(analysis; immunology; metabolism); Immunoglobulin Variable Region(biosynthesis; genetics); Influenza A virus(immunology); Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Models, Animal; Nucleoproteins(immunology; metabolism); Protein Binding(genetics; immunology); RNA-Binding Proteins; Viral Core Proteins(immunology; metabolism)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>169</Volume>
                <Issue>10</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>NP383-391</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SRYWAIRTR</LinearSequence>
                        <StartingPosition>383</StartingPosition>
                        <EndingPosition>391</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q91UL1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>132504</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>P. 5572</LocationOfData>
                <EpitopeId>60867</EpitopeId>
                <ReferenceStartingPosition>383</ReferenceStartingPosition>
                <ReferenceEndingPosition>391</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6B (ii)</LocationOfData>
                        <TCellId>20336</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000088</OrganismId>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>190</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>132504</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Influenza A virus (A/X-31(H3N2))</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>One injection of 300 hemagglutinating units of influenza A virus X-31.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SRYWAIRTR</LinearSequence>
                                            <StartingPosition>383</StartingPosition>
                                            <EndingPosition>391</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q91UL1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>132504</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Spleen cells from mice infected 3 wk earlier were restimulated in vitro for 6 days with autologous NP383-391 peptide-pulsed spleen cells and then were further restimulated for 7 days with peptide-pulsed irradiated syngeneic spleen cells that served as APCs.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                            <SourceOrganismId>10000088</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>190</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP383-391</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SRYWAIRTR</LinearSequence>
                                        <StartingPosition>383</StartingPosition>
                                        <EndingPosition>391</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q91UL1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>132504</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Strong lysis was observed for NP383-391-stimulated effector cells (of which 97.5% are CD8&lt;SUP&gt;+&lt;/SUP&gt; and of those 40% express Vβ8.1) from influenza-infected C57BL/6 Dbnull Kbnull, B*27052/Kb transgenic mice when tested on NP383-391-pulsed target cells. Similar results were seen in fully human HLA-B*27052 transgenic mice.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP418-426</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LPFDRTTVM</LinearSequence>
                        <StartingPosition>418</StartingPosition>
                        <EndingPosition>426</EndingPosition>
                        <SourceMolecule>
                            <IedbAccession>SRC124</IedbAccession>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>P. 5576</LocationOfData>
                <EpitopeId>38469</EpitopeId>
                <ReferenceStartingPosition>418</ReferenceStartingPosition>
                <ReferenceEndingPosition>426</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>This epitope was first identified by screening influenza A X-31 protein sequences for the HLA-B7 binding motif. This epitope is said to be conserved between influenza strains PR8 and X-31, which is expected given the PR8 origin of the internal proteins of reassortant virus X-31. Nevertheless, the published sequence for X-31 NP has a V425I substitution.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 7B (i)</LocationOfData>
                        <TCellId>20524</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000086</OrganismId>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>251</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>132504</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Influenza A virus (A/X-31(H3N2))</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>One injection of 300 hemagglutinating units of influenza A virus X-31.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>LPFDRTTVM</LinearSequence>
                                            <StartingPosition>418</StartingPosition>
                                            <EndingPosition>426</EndingPosition>
                                            <SourceMolecule>
                                                <IedbAccession>SRC124</IedbAccession>
                                            </SourceMolecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Spleen cells from mice infected 3 wk earlier were restimulated in vitro for 7 days with autologous NP418-426 peptide-pulsed spleen cells and then were further restimulated for 7 days with peptide-pulsed irradiated syngeneic spleen cells that served as APCs.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                            <SourceOrganismId>10000086</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>251</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP418-426</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LPFDRTTVM</LinearSequence>
                                        <StartingPosition>418</StartingPosition>
                                        <EndingPosition>426</EndingPosition>
                                        <SourceMolecule>
                                            <IedbAccession>SRC124</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Strong lysis was observed for NP418-426-stimulated effector cells (of which 96.6% are CD8&lt;SUP&gt;+&lt;/SUP&gt; and of those 33% express Vβ6) from influenza-infected C57BL/6 Dbnull Kbnull, B*07021/Kb transgenic mice when tested on NP418-426-pulsed target cells. Unlike NP418-426, the X-31 hemagglutinin peptide HA339-347 (VPEKQTRGL), which was also predicted by motif analysis to be restricted by HLA-B7, failed to produce any significant induction of CD8&lt;SUP&gt;+&lt;/SUP&gt; CTLs from flu-infected hybrid HLA-B7 transgenic  mice.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP366-372</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ASNENMETM</LinearSequence>
                        <StartingPosition>366</StartingPosition>
                        <EndingPosition>374</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q91UL1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>132504</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>P. 5572</LocationOfData>
                <EpitopeId>4602</EpitopeId>
                <ReferenceStartingPosition>366</ReferenceStartingPosition>
                <ReferenceEndingPosition>374</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6A (i)</LocationOfData>
                        <TCellId>20686</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>132504</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Influenza A virus (A/X-31(H3N2))</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>One injection of 300 hemagglutinating units of influenza A virus X-31.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>ASNENMETM</LinearSequence>
                                            <StartingPosition>366</StartingPosition>
                                            <EndingPosition>374</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q91UL1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>132504</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Spleen cells from mice infected 3 wk earlier were restimulated in vitro for 6 days with autologous NP366-372 peptide-pulsed spleen cells and then were further restimulated for 7 days with peptide-pulsed irradiated syngeneic spleen cells that served as APCs.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                            <SourceOrganismId>10000067</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP366-372</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASNENMETM</LinearSequence>
                                        <StartingPosition>366</StartingPosition>
                                        <EndingPosition>374</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q91UL1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>132504</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Strong lysis was observed for NP366-374-stimulated effector cells (of which 96.7% are CD8&lt;SUP&gt;+&lt;/SUP&gt; and of those 33% express Vβ8.3) from influenza-infected C57BL/6 mice when tested on NP366-374-pulsed target cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

